INMB — INmune Bio Inc
NASDAQ · Healthcare · Biotechnology
$2.26
+$0.02 (+0.75%)
INmune Bio Inc (INMB) is a biotechnology company listed on NASDAQ. It is led by David J. Moss M.B.A., based in 225 NE Mizner Blvd., Boca Raton, FL, United States, 33432, with about 21 employees. INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; GOSH; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.
Latest reported INMB revenue for 2025-09-30 was $50.0K. Net income was -$6.5M. Revenue was up 0.0% from 2025-06-30 to 2025-09-30. INMB currently screens at market cap $33.5M.
Use this INMB page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the INMB quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the INMB SEC filings page. Lician reads the product cache first so this HTML stays unique to INmune Bio Inc even when a live quote feed is slow.
About INmune Bio Inc
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; GOSH; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.
INMB Key Statistics
Market Cap
$33.50M
Volume
60,726
Previous Close
$2.36
Day Range
$2.35 – $2.43
EPS
-$2.11
Revenue
$14.00K
Net Income
-$42.08M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-91.0%
Profit Margin
-300585.7%
Employees
21
INMB Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $14.00K | $155.00K | $374.00K | $181.00K |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$42.08M | -$30.01M | -$27.30M | -$30.34M |
| EPS (Diluted) | -$2.11 | -$1.67 | -$1.52 | -$1.88 |
Total Assets
$39.56M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$20.92M
Operating Cash Flow
-$33.36M
Free Cash Flow
$0.00
INmune Bio Inc Company Information
- President, CEO, Treasurer, Secretary & Director
- David J. Moss M.B.A.
- Headquarters
- 225 NE Mizner Blvd., Boca Raton, FL, United States, 33432
- Website
- www.inmunebio.com
- Phone
- 561 710 0512
- IPO / Founded
- 2019-02-04
- Sector
- Healthcare
- Industry
- Biotechnology